This article is for medical information and pre-consultation reference only. It does not replace diagnosis, prescription, or individualized medical advice. Availability, indications, and regulatory status may change over time and should be confirmed through qualified professionals and official sources.

Eli Lilly has become one of the most important companies in the global obesity drug market. From Tirzepatide to Retatrutide and oral GLP-1 development, the company is building a broad metabolic treatment portfolio.

Many analysts believe Lilly is not only trying to launch one successful drug, but to shape the next decade of obesity care.

Tirzepatide is associated with Mounjaro and Zepbound. It targets both GLP-1 and GIP receptors and has become a major driver of Lilly’s obesity and metabolic business.

Its success helped Lilly become a central player in the global weight-management market.

Retatrutide is viewed as a possible next-generation therapy because it targets GLP-1, GIP, and glucagon receptors.

Recent Phase III data have shown substantial average weight loss, with some results reaching approximately 24%-28% over longer study periods.

Lilly is also investing in oral obesity medications. Orforglipron is an oral small-molecule GLP-1 receptor agonist designed for once-daily use without injections.

Clinical studies have shown meaningful weight reduction in adults with obesity or overweight. Many analysts see it as a potential major oral treatment option.

Lilly is studying obesity-related treatments across sleep apnea, osteoarthritis pain, MASH, cardiovascular risk, and kidney disease.

This suggests that future obesity medications may become broader metabolic disease management tools rather than weight-loss therapies alone.

The global obesity market is currently led by Novo Nordisk and Eli Lilly. Novo Nordisk has Wegovy and Ozempic, while Lilly has Zepbound, Mounjaro, Retatrutide, and Orforglipron in its current and future portfolio.

Lilly’s pipeline is widely viewed as one of the strongest in the industry.

• What is Lilly’s most successful obesity drug? Tirzepatide is currently the key product.
• Is Retatrutide approved? Not yet. It remains in clinical development.
• What is Orforglipron? An oral GLP-1 receptor agonist that does not require injection.
• Which products are most closely watched? Retatrutide and Orforglipron.

Eli Lilly’s obesity pipeline includes established, next-generation, and oral treatment strategies.

Tirzepatide, Retatrutide, and Orforglipron may continue to shape the future of obesity and metabolic treatment.